CC
HAE icon

Clearline Capital’s Haemonetics HAE Stock Holding History

Clearline Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,857
Closed -$629K – 147
2021
Q4 		$629K Buy
+11,857
New +$722K 0.07% 105
2021
Q3 		– Sell
-23,198
Closed -$1.55M – 158
2021
Q2 		$1.55M Buy
+23,198
New +$1.64M 0.23% 76

Other funds holding HAE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
LCOV
London Company of Virginia Richmond, Virginia $17.5B AUM 29.92% 1-Year Est. Return
LCP
LGT Capital Partners Pfaeffikon, Switzerland $1.97B AUM 15.72% 1-Year Est. Return

Clearline Capital's HAE Position: Q1 2022 in Review

Clearline Capital sold out of Haemonetics (HAE) in Q1 2022, closing a stake of 11,857 shares — an estimated $629K sold.

Clearline Capital first reported a position in HAE in Q2 2021 and held it in 2 quarters. The position peaked at $1.55M in Q2 2021. 242 funds tracked by Wall St. Rank hold HAE as of Q1 2022.

  • Clearline Capital reported no remaining Haemonetics position as of Q1 2022 after selling out during the quarter.
  • Clearline Capital sold 11,857 Haemonetics shares in Q1 2022, an estimated $629K.
  • Clearline Capital first reported a position in Haemonetics in Q2 2021 and held it in 2 quarters.
  • Clearline Capital's Haemonetics position peaked at $1.55M in Q2 2021.
  • 242 funds tracked by Wall St. Rank held Haemonetics as of Q1 2022.

Based on Clearline Capital's 13F filing for Q1 2022, filed 16 May 2022.